Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 9—September 2024
CME ACTIVITY - Research

Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1

Viivi NevanlinnaComments to Author , Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Author affiliations: Tampere University, Tampere, Finland (V. Nevanlinna, R. Huttunen, T. Luukkaala, S. Rantala); Tampere University Hospital, Tampere (V. Nevanlinna, R. Huttunen, T. Luukkaala, S. Rantala); Fimlab Laboratories, Tampere (J. Aittoniemi)

Main Article

Table 2

Disease severity among 159 episodes of Streptococcus dysgalactiae subspecies equisimilis bacteremia during November 2015–November 2019, Finland*

Characteristic Total, n = 159 Survivors, n = 150 Nonsurvivors, n = 9 p value
Admitted to intensive care unit
11 (7)
8 (5)
3 (33)
0.017
Needed mechanical ventilation 3 (2) 2 (1) 1 (11) 0.161
Needed continuous renal replacement therapy 1 (1) 1 (1) 0 NA
Needed hemodialysis 1 (1) 1 (1) 0 NA
Needed vasopressors
15 (9)
12 (8)
3 (33)
0.041
Lowered level of consciousness† 37 (23) 31 (21) 6 (67) 0.005
Unconscious
7 (4)
4 (3)
3 (33)
0.004
Hypotension‡ 36 (23) 30 (20) 6 (67) 0.005
Septic shock§ 18 (11) 13 (9) 5 (56) 0.001
Disseminated intravascular coagulation¶ 6 (4) 5 (3) 1 (11) 0.299
Multiorgan failure#
12 (8)
8 (5)
4 (44)
0.002
Underwent surgical intervention 38 (24) 33 (22) 5 (56) 0.037

*Values are no. (%) except as indicated; p values compare survivors and nonsurvivors. NA, not applicable. †Lowered level of consciousness (unconscious or confusion) >1 time during the first 2 days after positive blood culture. ‡Systolic blood pressure <90 mm Hg >1 time during days 0–2 after positive blood culture. §Use of vasopressor and blood lactate level >2 mmol/L >1 time during days 0–2 after positive blood culture. ¶Platelet counts <100 × 109/L. #Observed >3 concomitant organ failures.

Main Article

1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.

Page created: July 02, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external